The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.

Start Date09 Jan 2023

Sponsor / Collaborator

Oregon Health & Science University

100 Clinical Results associated with Ulipristal Acetate

100 Translational Medicine associated with Ulipristal Acetate

100 Patents (Medical) associated with Ulipristal Acetate

1,012

Literatures (Medical) associated with Ulipristal Acetate

01 Mar 2025·Brain Research

Long-term impact of congenital Zika virus infection on the rat hippocampus: Neuroinflammatory, glial alterations and sex-specific effects

Article

Author: Roehe, Paulo Michel ; Dos Santos, Adriana Souza ; de Aguiar, Gabrielle Batista ; Rieder, Alessandra Schmitt ; Pereira, Lenir Orlandi ; de Almeida, Wellington ; Dalmaz, Carla ; Netto, Carlos Alexandre ; Carvalho, Andrey Vinicios Soares ; Bohn, Anna Luísa Lothhammer ; da Costa, Meirylanne Gomes ; Teixeirad, Thais Fumaco ; Wyse, Angela Terezinha de Souza ; Martini, Ana Paula Rodrigues ; Varelad, Ana Paula Muterle ; Smaniotto, Thiago Ângelo

Congenital Zika Syndrome (CZS) is a condition that arises when a neonate presents with abnormalities resulting from Zika virus infection during gestation. While microcephaly is a prominent feature of the syndrome, other forms of brain damage are also observed, often accompanied by significant neurological complications. It is therefore essential to investigate the long-term effects of CZS, with special attention to sex differences, particularly concerning hippocampal function, given its vulnerability to viral infections. The aim of this study was to evaluate the long-term impacts on cognitive and memory functions, as well as neuroinflammatory and glial alterations in the hippocampus, in offspring of both sexes exposed to a model of congenital Zika virus infection. Pregnant rats were subcutaneously inoculated with ZIKV-BR at a dose of 1 × 10^7 plaque-forming units (PFU mL^-1) of ZIKV isolated in Brazil (ZIKV-BR) on gestational day 18 (G18). From postnatal day 70, the animals underwent behavioral tests. On postnatal day 80, the animals were euthanized, and hippocampal samples were collected for biochemical and histological analyses. In the open field test, females displayed more exploratory behavior and less grooming, while no significant differences in locomotion were observed between the sexes. Additionally, ZIKV-exposed females showed a reduction in grooming behavior compared to ZIKV-exposed males. In the memory test, males in the ZIKV group exhibited greater memory impairment, spending more time to locate the correct quadrant, while females showed relatively better performance. Neuroinflammatory markers, such as TNF-α, were significantly elevated in the hippocampus of ZIKV-exposed animals, regardless of sex. However, microglial and astrocytic responses, indicated by higher IBA1 and GFAP density, were only observed in male ZIKV rats. In conclusion, our findings suggest that congenital ZIKV exposure leads to sex-specific behavioral and neuroinflammatory alterations. While both males and females exhibited some behavioral changes, males were more significantly impacted in memory performance. Additionally, increased neuroinflammatory markers and glial activation were observed in the hippocampus of ZIKV-exposed animals, with a pronounced response in males. These results highlight the long-term impact of ZIKV infection on neurodevelopment, emphasizing the importance of considering sex differences in studies of congenital ZIKV syndrome.

01 Mar 2025·Theriogenology

Foals born alive from mares with ultrasonographically assessed placental abnormalities: Neonatal health and development up to weaning compared to foals from healthy mares

Article

Author: Debes, Leonie ; Blanco, Miguel ; Venner, Monica ; Sieme, Harald ; Sielhorst, Jutta ; Koether, Karoline ; Vervuert, Ingrid

Little is known about the health status of foals born alive from mares treated for placental disease. The aims of the present study were (1) to compare the neonatal health status and health development during the rearing period of foals born from mares treated for ultrasonographically assessed placental abnormalities (UPA) to age-matched healthy foals from the same warmblood stud and (2) analyze the influence of mare's placental health on colostrum quality. Foals (n = 127) born from mares with UPA (UPA group; P) in 2017-2019 were compared to 127 foals born from healthy mares (control group; C). Sixty-six UPA mares showed subclinical placental abnormalities (PSc1) and 61 mares showed clinical placental abnormalities (PSc2). The colostrum quality assessed by refractometry showed that healthy mares had 42 excellent (>30 %), 73 good (20-30 %) and 6 poor (<20 %) colostrum, whereas UPA mares showed 29 excellent, 66 good and 26 poor colostrum quality (P < 0.001). The administration of high-quality colostrum was more frequent in the UPA group (17.5 %) than in C (7.9 %; P = 0.024). The mean (±SD) gestation length of UPA mares was shorter (330 ± 11 days) and foal birth weight lower (54.2 ± 7.3 kg) compared to the healthy pregnancies (335 ± 11 days; P = 0.002 and 57.0 ± 6.6 kg; P < 0.001). The number of foals with a reduced immunoglobin G concentration 14 h postpartum was significantly higher in PSc2 (P = 0.007). Foals born from UPA mares received foreign plasma (P 25.4 % vs C 4.2 %; P = 0.028) more frequently. Premature placental separation, the occurrence of the retention of fetal membranes, placental weight, foal vitality and the white blood cell count did not differ between groups. Regarding the health status of the foal in the neonatal period (1-14 days postpartum), 10 foals (8.1 %) born from UPA pregnancies showed maladjustment syndrome, whereas none of the foals in the control group showed this condition (P < 0.001). Foals from UPA mares developed diarrhea more often (P 31.4 % vs C 19.9 %; P = 0.042), whereas omphalitis, pneumonia, sepsis, meconium obstipation and contracted tendons did not differ between the groups. Multimorbidity and treatment were more frequent in foals born from UPA pregnancies (P 12.8 % vs C 4.7 %; P = 0.004 and 59.6 % vs 40.4 %; P = 0.007). In conclusion, foals born alive from UPA mares face decreased immunity and an increased risk of disease during the first 14 days postpartum. The study underlines that colostrum supplementation from a healthy mare seems essential in UPA pregnancies.

01 Feb 2025·Life Sciences

Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities

Review

Author: Segars, James H ; Macri, Valeria I ; Ploumaki, Ioanna ; Islam, Md Soriful

Progesterone (P4) is a vital female sex hormone involved in various physiological processes, including the maintenance of the endometrium, mammary gland development, and bone health. Beyond its reproductive roles, P4 is implicated in the pathogenesis of hormone-dependent conditions like uterine fibroids, the most common benign tumors in women, which can severely affect quality of life and fertility. Traditionally, estrogen was considered the primary driver of fibroid growth, but recent research highlights the significant role of P4 in fibroid growth. P4 interacts with progesterone receptors (PRs) and non-genomic membrane receptors (mPRs and PGRMCs) to activate signaling pathways that enhance tumor growth and survival. P4 promotes vascular changes that improve the blood supply to fibroids and modifies the extracellular matrix, a key component of fibroid structure. This understanding has led to the investigation of selective progesterone receptor modulators (SPRMs) as potential therapies for fibroids. Clinical trials have demonstrated the effectiveness of SPRMs like mifepristone, asoprisnil, and ulipristal acetate in reducing fibroid size and symptoms, though concerns about safety, particularly with long-term use, remain. Newer SPRMs, such as vilaprisan, show promise, but further research is necessary to assess the long-term safety and effectiveness. This review discusses the mechanisms by which progesterone contributes to fibroid growth and examines clinical effectiveness of SPRMs as potential treatments for uterine fibroids.

News (Medical) associated with Ulipristal Acetate

27 Aug 2024

·www.prnewswire.com

ScaleReady announces the inaugural G-Rex® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine

ST. PAUL, Minn., Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of Stanford Medicine's LCGM's G-Rex platform for CAR-T cell therapy manufacturing, which will be offered to internal investigators and external developers who are seeking its development and manufacturing services. "Stanford's LCGM anticipates a need to support a greater number of clinical trials and the G-Rex Grant will be used to help meet that need," said Dr. Feldman. "We are honored to award the inaugural G-Rex Grant to Dr. Feldman and his team at Stanford Medicine LCGM. Stanford University is a world-class institution with faculty who have a reputation for innovative and ground-breaking achievements. Their work aligns with Wilson Wolf's mission of bringing hope to cancer patients, one G-Rex at a time" said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. As part of the G-Rex Grant, Stanford Medicine LCGM will deploy their G-Rex-centric manufacturing process in an upcoming Phase 1 trial for GPC2+ pediatric neuroblastoma and medulloblastoma. Previously, the FDA had recommended sponsors develop and implement potency assays earlier in the clinical trial process. With that objective, Stanford Medicine LCGM plans to implement Bio-Techne's leading automated multiplexing immunoassay platform, Ella™, as a potency assay for final drug product release. Furthermore, Stanford Medicine LCGM will collaborate with CellReady, the world's first and only G-Rex based contract development and manufacturing organization (CDMO), to leverage their proven capacity to quickly create G-Rex master batch records that establish manufacturing simplicity, efficiency, and repeatability. Additionally, Stanford Medicine LCGM plans to further develop a novel technology (developed by Wilson Wolf) that enables closed-system T cell purification to be done directly in a G-Rex device, without the need for expensive ancillary equipment. ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. About ScaleReady ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact [email protected]. About Wilson Wolf Manufacturing Wilson Wolf () is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne Corporation Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416 About CellReady LLC CellReady is the world's first and only G-Rex® centric contract development and manufacturing organization (CDMO) specializing in G-Rex® based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. SOURCE Bio-Techne Corporation

Cell TherapyImmunotherapyGene Therapy

08 Aug 2024

·www.biospace.com

Gameto Expands Executive Team with the Addition of Teri Loxam as Chief Financial Officer

NEW YORK, April 28, 2023 /PRNewswire/ -- Gameto, a female-led biotech company developing therapies to improve the female reproductive journey, today announced the expansion of its executive team with the appointment of Teri Loxam as its first Chief Financial Officer. In this new role, Teri will oversee Gameto's financial function, as well as play a key role in overall company strategy. "Teri is a proven CFO and an impressive female leader, whose decades of experience will immediately add value to our company," said Dina Radenkovic, co-founder and CEO of Gameto. "Her depth of knowledge in capital markets and financing in the biotechnology and pharmaceutical industries comes at an exciting time for the company as we work on clinical development and go-to-market strategy for our lead program, Fertilo, to make the IVF process shorter, safer and more effective for women. Teri's personal passion for women's health is extremely important to us as we continue to grow." Teri joins Gameto with over 20 years of diverse experience in strategy, investor relations and finance across the pharmaceutical, biotech, and TMT industries. Prior to joining Gameto, Teri was Chief Operating Officer & Chief Financial Officer at Kira Pharmaceuticals, a clinical-stage biotech company developing transformative therapies for people with complement-mediated diseases. There, she built financial and operational functions across the U.S. and China locations to get the company public-ready. Prior to Kira, Teri served as CFO of SQZ Biotechnologies, a novel cell therapy company developing treatments for cancer, infectious disease and other serious conditions, where she raised over $200M, including taking the company public in October 2020. Prior to joining SQZ, Teri held various positions at Merck, IMAX Corporation, and Bristol-Myers Squibb. Teri is also a member of the board of directors and audit chair of Vaxcyte, Inc. and Cardiol Therapeutics, Inc. She has a B.S. in Biology from the University of Victoria, B.C. Canada and an MBA from the University of California, Irvine. "Gameto's highly innovative platform and dedication to improve and support women's health is impressive," said Teri Loxam, Chief Financial Officer of Gameto. "I am eager to work with a talented team of professionals who are passionate about transforming the traditional IVF processes and advancing developments for women." Teri's appointment is one of many new senior hires this year. Gameto recently appointed Jean-Pierre Gotteland as Head of Development to the management team. Prior to joining Gameto, Jean-Pierre was Chief Scientific Officer and Head of R&D at ObsEva SA, a clinical-stage biotech company developing innovative women's reproductive health therapeutics. There, he led the development and approval of linzagolix, for uterine fibroids, and brought to clinical trials nolasiban, for increasing live birth rate following IVF. Jean-Pierre also served as Chief Development Officer at PregLem SA where he led the development and EU approval of ulipristal acetate for uterine fibroids and infertility. Prior to joining PregLem, Jean-Pierre held various R&D positions at Serono, a world-leading pharmaceutical company before its acquisition by Merck KgA. Jean-Pierre will facilitate clinical development of Gameto's lead program, Fertilo. These new senior hires expand the multidisciplinary team of stem cell engineers, computational biologists, embryologists and physicians Gameto has brought together. About Gameto Based in New York and Madrid, Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Gameto brings together an experienced scientific management team with vision and passion to develop a product offering that will support women throughout their reproductive journey. Gameto is currently working on its first program, Fertilo, a product for IVF and egg freezing, aiming to make the process shorter, safer and more effective. The preclinical studies for Fertilo found that it can increase egg yield per cycle and maturation for both conventional and reduced stimulation cycle. Gameto is currently conducting preclinical studies with partners Inception Fertility, Spring Fertility, Extend Fertility, RMA, Pozitivf, Ovation Fertility, ReproART, Clinica Tambre, and Hospital Ruber Internacional, Eugin Group. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and leader in the fertility space Martin Varsavsky as Chairman. For more information, go to gametogen.com or follow us on Twitter and Instagram @gametogen.

Executive ChangeDrug Approval

26 Apr 2024

·www.prnewswire.com

BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY

MINNEAPOLIS, April 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP), a first of its kind ocular biomarker kit, as a point-of-care application. Novomol-Dx is a molecular diagnostics company focused on commercializing tests for the diagnosis and treatment of ophthalmic diseases utilizing biomarkers discovered over the last decade at Narayana Nethralaya Foundation, in association with Grow Laboratories & Narayana Nethralaya, a specialty eye care hospital chain in Bangalore India. The BMP kit runs on Bio-Techne's Ella™, a benchtop automated immunoassay platform leveraging Bio-Techne's R&D Systems branded reagents to deliver accurate, reliable, and highly reproducible data in less than 90 minutes. Ella's microfluidic-based cartridges with separate channels enable precision multiplexing in a hands-free system, making it ideal for diagnostic clinical use. Novomol-Dx relied on a proprietary algorithm to develop the normative data, disease-associated data, and AI-based predictive algorithms for ocular surface and retinal conditions. The complete solution is branded as BioM-Pathfinder. The novel applications for the BMP kit are in Dry Eye Disease, Diabetic Retinopathy and patient stratification or monitoring associated with ocular surgeries and treatments. "The BMP kit's ability to produce clinically actionable data using tear samples is a game-changer for the diagnosis of these conditions. This kit fills a significant unmet need, with an estimated 15 million suffering from various ophthalmic diseases in India. Beyond ocular applications, we believe the underlying technology is potentially relevant for disease-associated diagnostic or prognostic applications in the future," stated Dr. Rohit Shetty, Chairman at Narayana Nethralaya. "There is a great need for improved ocular diagnostic tools, and the BMP kit will save time by enabling an accurate diagnostic solution to the millions impacted by ophthalmic diseases," said Dr. Naren Shetty, Vice-Chairman of Narayana Nethralaya. "The BMP multi-analyte kit holds great promise for the potential use of Ella in proteomic diagnostic applications," commented Will Geist, President of Bio-Techne's Protein Sciences Segment. "We are happy to partner with this leading ocular biomarker research group and eye care institute to deliver a much-needed diagnostic tool for patients impacted by these diseases." "We are excited to be able to translate the years of biomarker research in eye diseases to an application that can benefit clinicians and patients," said Dr. Arkasubhra Ghosh, Director of GROW research labs at Narayana Nethralaya Foundation. "The multiple biomarker diagnostic design establishes a platform for future expansion to broader disease applications across ophthalmic conditions, potentially including a non-invasive tear-based diagnosis for systemic conditions." About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at Facebook, LinkedIn, Twitter or YouTube. About Novomol-Dx Novomol-Dx is a start-up collaborative initiative of Narayana Nethralaya Foundation to bring out the solutions researched at their Grow Laboratories to the local India and international markets. Narayana Nethralaya group of hospitals are one of the best hospitals in India known for their quality care. Novomol-Dx is formed by a team of expert professionals with huge years of experience in the related field and have been associated with setting up successful multinational ventures. For more details about Novomol-DX, please visit . About Bio-Techne Corporation (NASDAQ: TECH) Contact: David Clair, Vice President, Investor Relations & Corporate Development [email protected] 612-656-4416 SOURCE Bio-Techne Corporation

Diagnostic Reagents

100 Deals associated with Ulipristal Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D09687	Ulipristal Acetate	G03XB02 G03AD02	DB08867

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pregnancy	US	Laboratoire HRA Pharma SA	13 Aug 2010
Contraception	LI	Laboratoire HRA Pharma SA	15 May 2009
Contraception	IS	Laboratoire HRA Pharma SA	15 May 2009
Contraception	EU	Laboratoire HRA Pharma SA	15 May 2009
Contraception	NO	Laboratoire HRA Pharma SA	15 May 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Leiomyoma	NDA/BLA	EU	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	NDA/BLA	LI	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	NDA/BLA	IS	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	IS	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	LI	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	EU	Gedeon Richter (UK) Ltd.	22 Feb 2012
Leiomyoma	Preclinical	NO	Gedeon Richter (UK) Ltd.	22 Feb 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04291001 (CTgov)	Early Phase 1	Contraception	40	ENG implant (ENG Implant Alone)	gfnnekfkzm(ateiydhbee) = cfsdzdqeyp wewcbgyljf (qnygkhrsuq, hmxrkyaeli - glxiwwezrt) View more	-	12 Jul 2024
				ENG implant+oral ulipristal acetate (ENG Implant Plus Oral UPA)	gfnnekfkzm(ateiydhbee) = mcmeuejpkg wewcbgyljf (qnygkhrsuq, vdvtiunynj - oanmuslgon) View more
NCT02213081 (CTgov)	Phase 4	Endometriosis \| Pelvic Pain	1	Ulipristal	iltvqohqrd(obvyfazxmh) = kdwqfbimsl buypcofsvg (hrzuhprvwd, graanrsdmc - qhcqrnwoah) View more	-	16 May 2024
NCT00551616 (CTgov)	Phase 3	Contraception	2,221	CDB-2914 (CDB-2914)	ucwgfephdi(blyregvwym) = ynpkhfmrdv kbgachhmfg (ruscnqsinb, hqymrlzyhh - kcvdrsnkdf) View more	-	16 Mar 2022
				Levonorgestrel (Levonorgestrel)	ucwgfephdi(blyregvwym) = iykmihbvrd kbgachhmfg (ruscnqsinb, axdobalpxj - lksrxjcdlq) View more
ACR2021	Phase 3	Rheumatoid Arthritis	905	UPA 15 mg + csDMARDs in bDMARD-IR patients	bltlkfcqvr(dhmelkleaz) = Among bDMARD-IR patients, the median (95% CI) time to 50% improvement in pain was longer in SELECT-BEYOND versus SELECT-CHOICE (16 [12, 20] versus 8 [8, 12] weeks) zszhcjmhes (lncqaghhtd ) View more	Positive	07 Nov 2021
				UPA 15 mg + csDMARDs in csDMARD-IR patients
EULAR2021	Not Applicable	Arthritis, Psoriatic \| Ankylosing Spondylitis	2,102	UPA 15 mg QD	kkcsprtfeo(dujfbttchc) = uwnzemupxl xmshxypmqp (ycruefdudl )	-	02 Jun 2021
				UPA 30 mg QD	kkcsprtfeo(dujfbttchc) = pdybjdohrq xmshxypmqp (ycruefdudl )
NCT00411684 (CTgov)	Phase 3	Contraception	1,623	CDB-2914	(sknkpgjtgj) = vdeouamqhx thjwvixpbf (whpualownn, oknsoopoyg - ntwpwgojdf) View more	-	03 May 2021
NCT01629563 (PEARLIV \| PEARL IV, CTgov)	Phase 3	Leiomyoma	451	PGL4001 5 mg (Ulipristal Acetate (PGL4001) 5mg)	ooeudfdoxs(efmatvcfbz) = hggmnaguzd jyhvanaawn (yqfxreneac, fsxrdflele - ibptmnzjqe) View more	-	04 Sep 2019
				PGL4001 10 mg (Ulipristal Acetate (PGL4001) 10mg)	ooeudfdoxs(efmatvcfbz) = uakieyphdh jyhvanaawn (yqfxreneac, opsylavcps - sdpywhgirk) View more
NCT02147197 (CTgov)	Phase 3	Abnormal uterine bleeding \| Leiomyoma	157	Placebo (Placebo)	zvnlszcxcq(xkkvouvzqn) = eqmgochcsy iumseeefev (lrmjuglkfl, epmfobzipr - vqxzkbowpn) View more	-	05 Apr 2019
				Placebo+Ulipristal acetate (UPA) (UPA 5 mg)	zvnlszcxcq(xkkvouvzqn) = woehohkphd iumseeefev (lrmjuglkfl, idgoscpgqx - kspegulbkp) View more
NCT00290251 (Pubmed \| Fertil Steril)	Phase 2	Uterine Fibroids	72	Ulipristal acetate	fzkudxbawb(jisjkdmetl) = xekyhchizb vwlnmcxwmz (gtdkawjmws ) View more	-	01 Apr 2019
				Placebo	qzcnvwithw(xcsozcfqts) = onzdajrgtl zmnfwldzau (iynmymszvw ) View more
NCT02147158 (Pubmed \| Obstet Gynecol)	Phase 3	Uterine Fibroids	432	5 mg ulipristal acetate	(qhrjsyypkv) = yodvmliveg slmdqcawey (kssvykrwts, 33.3 - 51.1) View more	Positive	01 Nov 2018
				10 mg ulipristal acetate	(qhrjsyypkv) = ixniigvrxf slmdqcawey (kssvykrwts, 45.5 - 63.8) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis